Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Ligand sells Marathon assets to CoPharma

Jan. 14, 2000

Japanese marketing approval no longer sought for Mochida's TNF

Jan. 12, 2000

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

Jan. 11, 2000

New developments announced for AltaRex's ovarian cancer therapy

Jan. 6, 2000

Maxamine granted orphan drug status for AML

Jan. 5, 2000

Cell Genesys receives payment from Japan Tobacco

Jan. 3, 2000

Cel-Sci completes another study in head and neck cancer

Dec. 29, 1999

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Dec. 29, 1999

Biomira's BLP25 liposome technology offers promise as cancer therapy

Dec. 29, 1999

SuperGen acquires equity interest in AVI BioPharma and negotiating rights to Avicine

Dec. 28, 1999

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...